Loading...
Loading...
BioLineRx
BLRX announced today that it intends to conduct an interim analysis
of the Phase II/III CLARITY trial of BL-1020, a first in class, orally
available, GABA-enhanced antipsychotic for the treatment of
schizophrenia. The interim analysis, which is expected to be finalized
in the first quarter of 2013, will be performed on data of approximately
235 randomized patients from 27 sites in Romania and India. The primary
endpoint of the analysis will be the six-week effect of the drug on
cognitive function, which is a principal deficit in schizophrenia
patients.
Dr. Kinneret Savitsky, CEO of BioLineRx, stated, “The recent re-analysis
of BL-1020's EAGLE Phase IIb study, showing a substantially greater
See full press release© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in